British Journal of Haematology | Wiley Online Library
OPTIMUM - MUK Nine Trial - Multiple Myeloma Clinical Trials
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Suggested treatment options for newly diagnosed multiple myeloma (MM)... | Download Scientific Diagram
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica
3613-Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) SUPERSEDED | eviQ
Suggested treatment options for newly diagnosed multiple myeloma (MM)... | Download Scientific Diagram
Multiple Myeloma Treatment Options | First Line Therapy
Frontiers | Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
PLEIADES study design. a Assessed using next-generation sequencing. CR,... | Download Scientific Diagram
A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma - ScienceDirect
View of Daratumumab (Darzalex SC) | Canadian Journal of Health Technologies
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management | Value-Based Cancer Care
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Leukemia
DRd - Darzalex + Revlimid + dex MYELOMA | ChemoExperts
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis | Advances in Therapy
Cancers | Free Full-Text | Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
